32 filings · most recent first
NUVL 8-K Filings
Nuvalent Inc Announces Election Of New Directors At 2026 Annual Meeting
Nuvalent Submits Nda For Neladalkib And Advances Zidesamtinib Review
Nuvalent Submits Nda For Neladalkib To Fda
Gsk To Acquire Nuvalent For 106 Billion In Oncology Deal
Nuvalent Reports Fourth Quarter And Full Year 2025 Financial Results And
Nuvalent Reports 14 Billion Cash And Outlines 2026 Milestones
Royalty Pharma Acquires Royalty Interest In Nuvalents Investigational Products
Nuvalent Inc Board Changes Resignation Of Dr Shair And Appointment Of Mr Squarer
Nuvalent Announces Pricing For Public Offering Of Common Stock
Nuvalent Announces Positive Pivotal Data For Neladalkib In Alkpositive Nsclc
Nuvalent Announces Third Quarter 2025 Financial Results And Pipeline Progress
Nuvalent Announces Nda Submission For Zidesamtinib
Nuvalent Inc Outlines Key 2025 Milestones And Clinical Trial Updates
Nuvalent Appoints New Director And Updates Stock Incentive Plan
Nuvalent Announces Pricing For Upsized Public Offering Of Common Stock
Nuvalent Announces Updated Clinical Data And Upcoming Phase 3 Trial For Cancer
Nuvalent Reports Second Quarter 2025 Financial Results And Business Updates
Nuvalent Announces Phase 3 Trial For Neladalkib In Advanced Alkpositive Nsclc
Nuvalent Announces Positive Pivotal Data For Zidesamtinib In Ros1Positive Nsclc
Nuvalent Inc Elects New Director And Announces Voting Results From Annual
Nuvalent Inc Announces Resignation Of Board Member Emily Conley
Nuvalent Reports Q1 2025 Financial Results And Leadership Promotions
Dr Gilliland Resigns From Nuvalent Board To Join Scientific Advisory Board
Nuvalent Reports Q4 And Full Year 2024 Financial Results And Business Updates
Nuvalent Announces Strong Financial Position And Pipeline Progress
Nuvalent Reports Q2 2024 Financial Results And Pipeline Updates
Nuvalent Initiates Phase 1A1B Clinical Trial For Her2Selective Inhibitor
Nuvalent Inc Announces 2024 Annual Meeting Voting Results
Fda Breakthrough Therapy Designation For Nvl655 Announced
Nuvalent Reports Q1 2024 Financial Results And Pipeline Updates
Nuvalent Reports Fourth Quarter And Full Year 2023 Financial Results
Nuvalent Announces Ontarget 2026 Plan And 2023 Yearend Cash Position